ENTITY
Wuxi Biologics

Wuxi Biologics (2269 HK)

585
Analysis
Health CareChina
WuXi Biologics (Cayman) Inc. is a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China, U.S., and Iceland. We provide a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. Our services are designed to help our global partners in shortening the cycle and lowering the cost of drug and medical device R&D through cost-effective and efficient solutions.
more
25 Apr 2025 11:21

Hong Kong Buybacks Weekly (Apr 25th): AIA, China Hongqiao, Swire Pacific

We analyzed the Hong Kong buyback data in the past week and highlight the top 3 companies that repurchased the most shares were AIA (1299 HK),...

Logo
305 Views
Share
24 Apr 2025 14:14

HK Short Interest Weekly: China Mobile, Sinopec, Smic, CNOOC, Meituan, Kuaishou

We analyzed the latest HK SFC report for aggregate short position as of Apr 11th and highlight short interest changes in China Mobile, Sinopec,...

Logo
562 Views
Share
17 Apr 2025 10:59

Hong Kong Buybacks Weekly (Apr 17th): AIA, Tencent, Wuxi Biologics

We analyzed the Hong Kong buyback data in the past week and highlight the top 3 companies that repurchased the most shares were AIA (1299 HK),...

Logo
658 Views
Share
14 Apr 2025 07:30

China & HK Strategy: Tariff Exemption Beneficiaries

​Lenovo, AAC Technologies, BYD Electronics, and Tcl Multimedia are set to benefit from Trump's tariff exemption, with potential for a rebound in...

Logo
396 Views
Share
13 Apr 2025 10:15

HK Short Interest Weekly: Pop Mart, Beigene, Xiaomi

We analyzed the latest HK SFC report for aggregate short position as of Apr 3rd and highlight short interest changes in Tracker Fund, Pop Mart,...

Logo
546 Views
Share
x